Warfarin-5-FU interaction - A consecutive case series

Jill M. Kolesar, Carrie L. Johnson, Betty L. Freeberg, Jordan D. Berlin, Joan H. Schiller

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18-74%, mean 44%). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66- 23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of 5-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.

Original languageEnglish (US)
Pages (from-to)1445-1449
Number of pages5
JournalPharmacotherapy
Volume19
Issue number12
StatePublished - 1999

Fingerprint

Warfarin
Fluorouracil
International Normalized Ratio
Drug Therapy
Prothrombin Time
Prodrugs
Observation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kolesar, J. M., Johnson, C. L., Freeberg, B. L., Berlin, J. D., & Schiller, J. H. (1999). Warfarin-5-FU interaction - A consecutive case series. Pharmacotherapy, 19(12), 1445-1449.

Warfarin-5-FU interaction - A consecutive case series. / Kolesar, Jill M.; Johnson, Carrie L.; Freeberg, Betty L.; Berlin, Jordan D.; Schiller, Joan H.

In: Pharmacotherapy, Vol. 19, No. 12, 1999, p. 1445-1449.

Research output: Contribution to journalArticle

Kolesar, JM, Johnson, CL, Freeberg, BL, Berlin, JD & Schiller, JH 1999, 'Warfarin-5-FU interaction - A consecutive case series', Pharmacotherapy, vol. 19, no. 12, pp. 1445-1449.
Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction - A consecutive case series. Pharmacotherapy. 1999;19(12):1445-1449.
Kolesar, Jill M. ; Johnson, Carrie L. ; Freeberg, Betty L. ; Berlin, Jordan D. ; Schiller, Joan H. / Warfarin-5-FU interaction - A consecutive case series. In: Pharmacotherapy. 1999 ; Vol. 19, No. 12. pp. 1445-1449.
@article{b5388a4e7a4e4765a4ee1850c65d5bc2,
title = "Warfarin-5-FU interaction - A consecutive case series",
abstract = "Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18-74{\%}, mean 44{\%}). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66- 23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of 5-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.",
author = "Kolesar, {Jill M.} and Johnson, {Carrie L.} and Freeberg, {Betty L.} and Berlin, {Jordan D.} and Schiller, {Joan H.}",
year = "1999",
language = "English (US)",
volume = "19",
pages = "1445--1449",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12",

}

TY - JOUR

T1 - Warfarin-5-FU interaction - A consecutive case series

AU - Kolesar, Jill M.

AU - Johnson, Carrie L.

AU - Freeberg, Betty L.

AU - Berlin, Jordan D.

AU - Schiller, Joan H.

PY - 1999

Y1 - 1999

N2 - Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18-74%, mean 44%). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66- 23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of 5-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.

AB - Five patients from a single institution received concomitant warfarin and 5-fluorouracil (5-FU) during a 3-year period. The mean weekly warfarin dose before starting chemotherapy was 40.66 mg and during chemotherapy it was 24 mg (p=0.0026). All patients required a warfarin dosage reduction (range 18-74%, mean 44%). Two patients were hospitalized, one with a major retroperitoneal bleed, the other for fresh-frozen plasma administration and observation. Maximum international normalized ratios (INRs) ranged from 3.66- 23.7. This series confirms a common, clinically significant interaction between warfarin and 5-FU. An interaction between capecitabine, the orally available prodrug of 5-FU, and warfarin also has been reported. We recommend weekly monitoring of prothrombin time and INR for all patients receiving concomitant warfarin and 5-FU or capecitabine.

UR - http://www.scopus.com/inward/record.url?scp=0032751138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032751138&partnerID=8YFLogxK

M3 - Article

C2 - 10600095

AN - SCOPUS:0032751138

VL - 19

SP - 1445

EP - 1449

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12

ER -